Oak Ridge Investments LLC cut its holdings in shares of Retrophin (NASDAQ:RTRX) by 26.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 359,545 shares of the biopharmaceutical company’s stock after selling 132,361 shares during the quarter. Oak Ridge Investments LLC’s holdings in Retrophin were worth $8,039,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Consonance Capital Management LP increased its holdings in shares of Retrophin by 4.0% during the fourth quarter. Consonance Capital Management LP now owns 3,644,438 shares of the biopharmaceutical company’s stock worth $76,788,000 after purchasing an additional 138,834 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Retrophin by 1.8% during the first quarter. Dimensional Fund Advisors LP now owns 925,792 shares of the biopharmaceutical company’s stock worth $20,701,000 after purchasing an additional 15,989 shares during the period. Northern Trust Corp increased its holdings in shares of Retrophin by 1.8% during the first quarter. Northern Trust Corp now owns 713,524 shares of the biopharmaceutical company’s stock worth $15,954,000 after purchasing an additional 12,513 shares during the period. Millennium Management LLC increased its holdings in shares of Retrophin by 1.8% during the fourth quarter. Millennium Management LLC now owns 558,260 shares of the biopharmaceutical company’s stock worth $11,763,000 after purchasing an additional 9,926 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Retrophin by 7.7% during the fourth quarter. Geode Capital Management LLC now owns 343,973 shares of the biopharmaceutical company’s stock worth $7,247,000 after purchasing an additional 24,615 shares during the period.

Retrophin opened at $28.38 on Thursday, according to Marketbeat. The company has a current ratio of 5.07, a quick ratio of 4.98 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.13 billion, a P/E ratio of -18.92 and a beta of 1.06. Retrophin has a 1 year low of $17.02 and a 1 year high of $29.77.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.25). The firm had revenue of $38.43 million for the quarter, compared to analyst estimates of $39.32 million. Retrophin had a negative return on equity of 20.27% and a negative net margin of 41.95%. The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.01 EPS. equities analysts expect that Retrophin will post -1.7 EPS for the current year.

Several research analysts have recently commented on the stock. ValuEngine raised shares of Retrophin from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 2nd. BidaskClub raised shares of Retrophin from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 16th. Finally, BMO Capital Markets lowered their target price on shares of Retrophin from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Wednesday, April 4th.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.